Cassava Sciences (NASDAQ:SAVA – Get Free Report) announced its earnings results on Monday. The company reported ($0.57) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.99) by $0.42, Zacks reports.
Cassava Sciences Trading Down 7.7 %
SAVA opened at $2.40 on Monday. The firm has a market capitalization of $115.46 million, a PE ratio of -1.74 and a beta of -0.95. Cassava Sciences has a twelve month low of $2.23 and a twelve month high of $42.20. The firm’s 50-day moving average price is $2.53 and its 200 day moving average price is $15.48.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright lowered shares of Cassava Sciences from a “buy” rating to a “neutral” rating and set a $116.00 target price on the stock. in a research report on Tuesday, November 26th.
About Cassava Sciences
Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
Further Reading
- Five stocks we like better than Cassava Sciences
- Why is the Ex-Dividend Date Significant to Investors?
- 4 Blockchain Stocks That Aren’t Coinbase
- How to trade using analyst ratings
- These 3 Tech Stocks Are Gaining Steam After NVIDIA’s Report
- Where to Find Earnings Call Transcripts
- These S&P 500 Stocks Have Low P/E Ratios — Time to Buy?
Receive News & Ratings for Cassava Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cassava Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
